Rubella - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rubella - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Rubella - Pipeline Review, H2 2015', provides an overview of the Rubella's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rubella
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rubella and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rubella pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rubella
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rubella pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rubella Overview 7
Therapeutics Development 8
Pipeline Products for Rubella - Overview 8
Pipeline Products for Rubella - Comparative Analysis 9
Rubella - Therapeutics under Development by Companies 10
Rubella - Therapeutics under Investigation by Universities/Institutes 11
Rubella - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Rubella - Products under Development by Companies 15
Rubella - Products under Investigation by Universities/Institutes 16
Rubella - Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
Beijing Tiantan Biological Products Co., Ltd. 18
Biological E. Limited 19
China National Pharmaceutical Group Corporation 20
Daiichi Sankyo Company, Limited 21
GlaxoSmithKline Plc 22
Organic Vaccines 23
Prometheon Pharma, LLC 24
Sinovac Biotech Ltd. 25
Zydus Cadila Healthcare Limited 26
Rubella - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Cell Therapy for Measles, Mumps and Rubella - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
measles + mumps + rubella + varicella vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
measles + mumps + rubella + varicella vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
measles + mumps + rubella + varicella vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
measles + mumps + rubella vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
measles + mumps + rubella vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
measles + mumps + rubella vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
measles + rubella + varicella vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
measles + rubella vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
measles + rubella vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
VN-0102 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Rubella - Recent Pipeline Updates 45
Rubella - Dormant Projects 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for Rubella, H2 2015 8
Number of Products under Development for Rubella - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Rubella - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 17
Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015 18
Rubella - Pipeline by Biological E. Limited, H2 2015 19
Rubella - Pipeline by China National Pharmaceutical Group Corporation, H2 2015 20
Rubella - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 21
Rubella - Pipeline by GlaxoSmithKline Plc, H2 2015 22
Rubella - Pipeline by Organic Vaccines, H2 2015 23
Rubella - Pipeline by Prometheon Pharma, LLC, H2 2015 24
Rubella - Pipeline by Sinovac Biotech Ltd., H2 2015 25
Rubella - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 26
Assessment by Monotherapy Products, H2 2015 27
Assessment by Combination Products, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Rubella Therapeutics - Recent Pipeline Updates, H2 2015 45
Rubella - Dormant Projects, H2 2015 46